

REPROCELL CHOOSES SCIENCE EXCHANGE AS THE PREFERRED PARTNER TO INCREASE ACCESSIBILITY OF ITS PREDICTIVE DRUG DISCOVERY SERVICES

Location: REPROCELL Europe Ltd. (Glasgow, UK)
Business Unit: REPROCELL Discovery
Date: November 13, 2017

Announcement — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research services and procurement of human biospecimens, announced today that REPROCELL has selected the Science Exchange platform as the primary marketplace to offer access to its predictive drug discovery assays for the biopharma research community.

With REPROCELL as one of Science Exchange’s qualified marketplace service providers, researchers now have access to a diverse range of preclinical assay services using fresh human tissues, stem cells and 3D models which offer the biopharma industry novel tools for investigating the safety and efficacy of new drug candidates early in the drug discovery process.

Through the Science Exchange platform, researchers are empowered to focus on innovation, while Science Exchange takes on the role of supporting the identification of new and novel service providers such as REPROCELL, management of a secure contracting process, and delivery of analytics to track performance and inform process improvement.

“Our predictive drug discovery services using fresh human tissues, stem cells and 3D models are instrumental for researchers in the biopharma industry understanding the safety and efficacy of drug candidates in early stage development and mitigate risk of unpredicted safety and efficacy findings at a later stage” said David Bunton, Ph.D., CEO of REPROCELL EUROPE Ltd and its Centre for Predictive Drug Discovery. “Our partnership with Science Exchange will enable researchers from all over the world to access our assay services while gaining the operational and service support that Science Exchange is known for in the scientific community.”

“The Science Exchange platform allows global biopharma researchers to source and secure research products and services in a highly compliant manner from a global network of 2,500+ commercial and academic research service providers,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are proud to add REPROCELL, a company well-known for its innovative stem cell technologies, preclinical assay services, and extensive repository of human tissue samples, to our network of qualified service pro-

viders – giving researchers access to a powerful tool for safety and efficacy investigation of new drug candidates via the Science Exchange platform.”

About Science Exchange — Science Exchange is the world’s leading and most secure platform for outsourced research, providing an efficient procure-to-pay platform for ordering 6,000+ services from a network of more than 2,500 qualified scientific service providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than \$58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.ScienceExchange.com. Follow the company on Twitter @ScienceExchange.

About REPROCELL Europe — REPROCELL Europe was created on the 1st of July 2016 from the merger of Biopta Ltd and Reinnervate Ltd. REPROCELL Europe offers the full range of life sciences research products and contract research services of the REPROCELL Group Brands (REPROCELL, Biopta, Reinnervate, Stemgent and BioServe) to markets worldwide. Through the ongoing research and development synergies within the Group, REPROCELL Europe aims to bring to market further unique products and services to accelerate research in stem cells, drug discovery, human tissues and 3D cell culture.

About REPROCELL — Headquartered in Yokohama (Japan), REPROCELL is an integrated research and medical company. Serving the global market, the REPROCELL Discovery business unit is focused on providing drug discovery services and products including human tissues and cutting-edge iPS stem cell technologies. Leveraging this history and strength, the REPROCELL Medical business unit (*formed 2017*) is pioneering stem cell-based applications for regenerative medicine therapies and human diagnostics. REPROCELL (<https://reprocell.com>) is a public company traded on the JASDAQ market. For more information on this press release contact your regional REPROCELL office (phone numbers and e-mails provided on the website listed above).

Follow us on social media:

Facebook: <https://www.facebook.com/REPROCELLglobal>

Twitter: <https://twitter.com/REPROCELLglobal>

LinkedIn: <https://www.linkedin.com/company/reprocell/>